Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02649517
Other study ID # 1801
Secondary ID
Status Recruiting
Phase N/A
First received January 4, 2016
Last updated January 5, 2016
Start date January 2016
Est. completion date October 2018

Study information

Verified date January 2016
Source Russian Academy of Medical Sciences
Contact Vyacheslav Ryabov, MD, PhD
Phone +73822553689
Email rvvt@cardio-tomsk.ru
Is FDA regulated No
Health authority Russia: Ministry of Health of the Russian Federation
Study type Interventional

Clinical Trial Summary

The purpose of the study is to investigate the clinical and morphological characteristics of chronic subclinical inflammation in the myocardium in patients with decompensated heart failure with ischemic systolic dysfunction.


Description:

Important reason for the development of chronic heart failure is a viral disease of the heart, the three phenotypes associated with: the presence of inflammation without viral agent, implying an autoimmune disease; presence of inflammation and persistent viruses; and the presence of persistent virus without signs of inflammation.

There is a group of patients with coronary heart disease, which on the background of optimal treatment is observed progression of clinical symptoms of coronary heart disease with the subsequent development of heart failure, leading to ischemic cardiomyopathy. Perhaps the reason for this is the combination of inflammatory and ischemic cardiomyopathies.

Inflammatory cardiomyopathy, involved in the pathogenesis of DCM, includes idiopathic, autoimmune and infectious subtypes. Inflammatory disease of the myocardium diagnosed by established histological, immunological and immunohistochemical criteria.

This study will include 60 patients with decompensated heart failure with ischemic left ventricular systolic dysfunction (LVEF <40%) were hospitalized not earlier than 6 months after myocardial revascularization. This group of patients will receive standard treatment, according to national guidelines RSC and ESC, to stabilize heart failure. All patients will be held PCI to exclude ischemic heart failure decompensation. Also, all patients will be performed endomyocardial biopsy as a result of immunohistochemical studies will be made on the separation of the virus and the virus-negative-positive group. After that, the group will be divided into subgroups: virus - and inflammation in the myocardium inflammation without viral antigen, viral inflammation of the presence of antigen and the group with the presence of viral antigen without any signs of inflammation in the myocardium.

The study is nonrandomized.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date October 2018
Est. primary completion date February 2018
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Men and women over the age of 18 years old and weighing up to 130 kg

- Clinical symptoms of decompensated heart failure in history

- Heart failure decompensation requiring hospitalization for at least 3 of the following symptoms: shortness of breath, or position orthopnea, rales, peripheral edema, jugular venous pulsations, signs of stagnation in the pulmonary circulation according to the X-ray of the chest

- Confirmed coronary heart disease with diastolic dysfunction (LVEF <40%) in history and at the time of admission

- The term of the inclusion of patients in the study did not earlier than six months after revascularization (PCI or CABG)

- Patients receiving medical treatment according to national guidelines RSC and ESC with individually tailored doses of drugs

Exclusion Criteria:

- The refusal of a patient to conduct the necessary studies

- Poor visualization of the heart when ultrasound

- Hemodynamically significant valvular heart disease

- Acute coronary syndrome

- ?hrombosis of the right atrium and right ventricle

- Condition after the operation, impeding access to the right ventricle (cava filters plication vena cava, Mustard or Senning operation on the d-transposition of the great arteries, a mechanical prosthetic tricuspid valve)

- Severe comorbidities

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Intervention

Procedure:
Endomyocardial biopsy
Endomyocardial biopsy will be performed through a puncture in the femoral vein. 3-6 samples taken under the control of myocardial echocardiography or flyuroskopii. Samples of biopsy material then transmitted Pathomorphology for immunohistochemistry, light microscope.

Locations

Country Name City State
Russian Federation Research Institutite for Cardiology Tomsk Tomskii region
Russian Federation Scientific and Research Institution of Cardiology of Siberian Department of RAMS Tomsk

Sponsors (1)

Lead Sponsor Collaborator
Russian Academy of Medical Sciences

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of inflammatory infiltrate in the myocardial tissue 6 month after PCI or CABG No
Secondary Incidence of the virus - positive inflammatory infiltrate in the myocardial tissue 6 month after PCI or CABG No
Secondary The most frequent viral agents in myocardial tissue in this region 6 month after PCI or CABG No
Secondary Incidence of the acute myocardial infarction 6 and 12 month after PCI or CABG No
Secondary Incidence of disturbance rhythm and conduction of the heart 6 and 12 month after PCI or CABG No
Secondary Left ventricular ejection fraction (Echo) 6 and 12 month after PCI or CABG No
Secondary ?nd-diastolic volume of the left ventricle (Echo) 6 and 12 month after PCI or CABG No
Secondary ?nd-systolic volume of the left ventricle (Echo) 6 and 12 month after PCI or CABG No
Secondary Incidence of the mortality 6 and 12 month after PCI or CABG No
Secondary Incidence of the stroke 6 and 12 month after PCI or CABG No
Secondary Incidence of hospitalizations for decompensation heart failure 6 and 12 month after PCI or CABG No
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Active, not recruiting NCT04562805 - Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT) N/A
Recruiting NCT05292079 - CAPTURER PMCF Study ( rEPIC04D )
Recruiting NCT05292092 - Essential Pro PMCF Study ( rEPIC04E )
Recruiting NCT05292118 - Navitian PMCF Study ( rEPIC04C )
Recruiting NCT05292014 - ANGIOLITE PMCF Study ( rEPIC04F )
Completed NCT05292105 - NC Xperience PMCF Study( rEPIC04B)
Completed NCT03076801 - Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease? N/A
Not yet recruiting NCT04153383 - Milrinone on Cardiac Performance During Off-pump Coronary Artery Bypass Surgery
Recruiting NCT02982434 - The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation Phase 2
Recruiting NCT02729064 - Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose Phase 1
Completed NCT02468401 - Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions N/A
Completed NCT02759406 - Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study N/A
Recruiting NCT01681381 - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization N/A
Completed NCT01699802 - Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa) N/A
Completed NCT01604213 - Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease Phase 4
Completed NCT01724567 - Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training N/A
Completed NCT01334268 - RESOLUTE China RCT N/A
Completed NCT02159235 - Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD) N/A